机构：[1]Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China临床药学部临床药学部四川省人民医院四川省肿瘤医院[2]Department of Information, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院四川省肿瘤医院[3]Department of Clinical Laboratory, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院四川省肿瘤医院[4]Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China
In December 2019, a severe outbreak of a novel coronavirus (COVID-19) occurred in the whole world, posing a great threat to people's health. With the outbreak and development of the epidemic, how to improve the cure rate, find effective drugs against this virus, has been the most urgent problem. Chloroquine (CQ) was verified effective against COVID-19 in vitro. As CQ's analogue, hydroxychloroquine (HCQ) was also reminded as a potential candidate for treating COVID-19. This review summarizes the latest clinical trials of CQ and HCQ against COVID-19 and its therapeutic regimen in China aiming to share their current usage to the whole world and provide insight into its appropriate future use in the treatment of COVID-19. Through searching the CNKI and Wangfang databases in Chinese language and PubMed, EMBASE, and Ovid databases in English language to identify published reports with the keywords including "coronavirus/COVID, chloroquine, hyroxychloroquine" in alone or combined, we found out the potential preclinical or clinical evidence for using CQ and HCQ against COVID-19. Consequently, we also searched the website of Chinese Clinical Trial Registry (http://www.chictr.org.cn/) till the day on 27th, June, 2020. This review found that there are 23 programs aimed to treat the different phases under COVID-19 pipeline in clinic with CQ and HCQ, totally. The inclusion criteria, exclusion criteria and therapeutic regimen were all shared to consult. Among them, seven have been canceled due to lack of patients or other objective factors. There are two trials have completed, which the potential relationship between usage and adverse reactions was discussed emphatically. Through literature research, we suggested that paid close attention to retinal toxicity and ophthalmologic adverse symptom of CQ and HCQ. And the outcome of HCQ in clinic shows better than CQ especially in protective effect with low dosage.
基金：
Science & Technology Program of Sichuan Province (Grant No. 2015JQO027, 2015ZR0160,2020YFS0412, 2020JDTD0029); the Healthy department of Sichuan Province (Grant No. 20PJ110, 20PJ116, 17ZD038);
Cadre Health Care Research Project of Sichuan Province (Grant No. 2019-801); Zambon Pharmaceutical Scientific Research Foundation of the Chengdu Pharmaceutical Association (Grant No. 201905); Sichuan Cancer Hospital & Institute Independently Funded the Project (Grant Nos. YB2019001).
第一作者机构：[1]Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
通讯作者：
通讯机构：[1]Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China[4]Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China
推荐引用方式(GB/T 7714)：
Yan Chen,TaiPeng Shen,LiJun Zhong,et al.Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.[J].FRONTIERS IN PHARMACOLOGY.2020,11:doi:10.3389/fphar.2020.01167.
APA：
Yan Chen,TaiPeng Shen,LiJun Zhong,ZhiXi Liu,XinWei Dong...&HongTao Xiao.(2020).Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use..FRONTIERS IN PHARMACOLOGY,11,
MLA：
Yan Chen,et al."Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.".FRONTIERS IN PHARMACOLOGY 11.(2020)
